Search the Newsreel

Orchestra BioMed Hldgs Market Sentiment

This article provides an overview of market sentiment for Orchestra BioMed Holdings Inc (OBIO), detailing analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from seven analysts with an average price target of $14, and lists recent analyst actions …

Nanobiotix SA (NBTX) Cash Flow

This article provides a detailed cash flow statement for Nanobiotix SA (NBTX), presenting annual and quarterly data from FY2012H1 to FY2024H2. It breaks down cash flows into operating, investing, and financing activities, along with key metrics like free cash flow and beginning/ending cash balances. …

Nanobiotix SA (NBTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Nanobiotix SA (NBTX), detailing its support, resistance, indicators, and moving averages. It summarizes the findings from various technical indicators like MACD, RSI, and STOCH, along with moving averages, to give a "Neutral" signal for the stock based …

OBIO|Orchestra Biomed Holdings Inc|Price:3.810|Chg%:-0.050

This article provides a comprehensive stock analysis of Orchestra BioMed Holdings Inc (OBIO) from TradingKey, highlighting its relatively healthy fundamentals, good growth potential (1113.12% revenue growth), and fair valuation. Institutional ownership is high, and analysts have a "Buy" rating with a target price of …

Orchestra Biomed Holdings Inc (OBIO) Income Statement

This article provides the quarterly and annual income statements for Orchestra Biomed Holdings Inc (OBIO), detailing various financial metrics such as total revenue, operating expenses, R&D expenses, operating profit, and net income over several fiscal quarters and years. It also includes frequently asked questions …

Orchestra Biomed Holdings Inc (OBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Orchestra Biomed Holdings Inc (OBIO) focusing on its dividend and stock split history. It indicates that the company has distributed $0.00 in dividends over the past five years and contains no specific dividend or stock split data. The …

Orchestra BioMed Holdings, Inc. Revenue Breakdown – NASDAQ:OBIO

Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) reported a total revenue of $33.48 million USD last year. The primary driver of this revenue was its Medical Device segment, contributing the entirety of the figure, a significant increase from $2.64 million USD in the previous year. …

Nanobiotix SA (NBTX) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial analysis of Nanobiotix SA (NBTX), focusing on its profitability and balance sheet. It includes current stock quotes, market capitalization, and links to more detailed financial and discussion content on the TradingKey platform. The content is presented as a general …

Orchestra Biomed Holdings Inc (OBIO) Valuation: PE, PB & Fair Value Analysis

Orchestra Biomed Holdings Inc (OBIO) currently has a valuation score of 7.62, placing it 154th out of 200 companies in the Healthcare Equipment & Supplies industry. Its P/E ratio stands at -3.95, indicating a significant deviation from both its recent high and low. Data …

Nanobiotix SA (NBTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of dividend and stock split history for Nanobiotix SA (NBTX). It states that the company has distributed $0.00 in dividends over the past five years and indicates no dividend data is available. The article also includes current stock performance …

Nanobiotix S.A. Revenue Breakdown – NASDAQ:NBTX

This article provides a brief overview of Nanobiotix S.A.'s revenue breakdown. Last year, the company generated $37.88 million USD in revenue, with its Nanotherapeutics segment being the top performer, contributing $33.45 million USD. France was the primary geographical contributor, also accounting for $33.45 million …

Nanobiotix SA Revenue Breakdown – TURQUOISE:NANOP

Nanobiotix SA's revenue breakdown for the last year shows total generated revenue of 32.59 million EUR. The Nanotherapeutics segment was the top performer, contributing 29.64 million EUR, a significant improvement from the previous year's negative figure. France was the primary geographical contributor, matching the …

NBTX|Nanobiotix SA|Price:39.310|Chg%:-0.240

This article provides a detailed financial overview of Nanobiotix SA (NBTX), including its current stock price, market performance across various timeframes, and key financial figures. It highlights analyst ratings, indicating a "Buy" consensus with a target price of $53.00, and lists technical indicators. The …

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Nanobiotix Shares Soar Nearly 5%, Targeting Resistance at €36.20

Nanobiotix shares gained almost 5%, reaching €32.76, making it one of the strongest performers in the SBF 120. This rebound follows a week of consolidation, pushing the stock closer to its MM20 moving average. The company's annual performance remains exceptionally strong, with a 622% …

Nanobiotix Shares Soar by 4.5%, Leading the SBF 120

Nanobiotix shares gained 4.25% to €34.36, leading the SBF 120 and moving above its short-term moving averages. The company's annual performance remains strong, driven by clinical advancements of its candidate JNJ-1900 (NBTXR3) and encouraging phase 2 results. The stock's current rebound comes after a …

Short Interest in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Grows By 79.5%

NBTX Q4 2025 Earnings: Significant EPS Miss Amid Clinical Pipeline Progress - Quarterly Earnings Report

Nanobiotix Provides First Quarter 2026 Operational and Financial Update

Nanobiotix (NBTX) Stock Forecast and Price Target 2026